Therapy of cutaneous mastocytosis is directed towards skin and systemic symptoms due to mediator release and targeted on skin lesions. Symptomatic therapy of cutaneous mastocytosis involves agents that inhibit the release of mediators or antagonize H1 and H2 receptors such as antihistamines ketodifen and Aspirin. Disodium cromoglycate has no effect of the cutaneous symptoms of cutaneous mastocytosis. Skin-targeted therapies that lead to a resolution of the lesions of cutaneous mastocytosis are psoralen-photochemotherapy and topical corticosteroid therapy either by occlusion or intralesional injection for a limited number of lesions. There is no treatment that permanently cures cutaneous mastocytosis and patient selection will therefore have to be made on the basis of the clinical manifestations, onset of disease, the probability of spontaneous involution and the severity of cutaneous and systemic symptoms.

Valent P, Horny H-P, Escribano L, Longley JB, Li QY, Schwartz LB, Marone G, Wolff K, Brunning RD, Parwaresch RM, Austen FK, Lennert K, Metcalfe DD, Vardim JW, Bennett JM: Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 2001;35:603–625.
Wolff K, Komar M, Petzelbauer P: Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001;25:519–528.
Soter NA, Austen KF, Wasserman SI: Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 1979;301:465–469.
Metcalfe DD: The treatment of mastocytosis: An overview. J Invest Dermatol 1991;96:55s–59s.
Barton J, Lavker RM, Schechter NM, Lazarus GS: Treatment of urticaria pigmentosa with corticosteroids. Arch Dermatol 1985;121:1516–1523.
Nafziger J, Arock M, Guillosson JJ, Weitzerbin J: Specific high affinity receptors for interferon-γ on mouse bone marrow-derived mast cells: Inhibiting effect of interferon-γ on mast cell precursors. Eur J Immunol 1990;20:113–117.
Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, Willemze R: Response to interferon α-2b in a patient with systemic mastocytosis. N Engl J Med 1992;326:619–623.
Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD: Treatment of three patients with systemic mastocytosis with interferon α-2b. Leuk Lymphoma 1996;22:501.
Christophers E, Hönigsmann H, Wolff K, Lagner A: PUVA treatment of urticaria pigmentosa. Br J Dermatol 1978;98:701–702.
Grauerns G, Roupe G, Swantech G: Decreased urinary histamine metabolite after successful PUVA treatment of urticaria pigmentosa. J Invest Dermatol 1981;76:1–3.
Vella Briffa D, Eady RA, James MP, Gatti S, Bleehan SS: Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa. Br J Dermatol 1983;109:67–75.
Kolde G, Frosch PJ, Czarnetzki BM: Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: Histomorphometric, ultrastructural and biochemical investigations. J Invest Dermatol 1984;83:175–178.
Czarnetzki BM, Rosenbach T, Kolde G, Frosch PJ: Phototherapy of urticaria pigmentosa: Clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes. Arch Dermatol Res 1985;277:105–113.
Mackey S, Pride HB, Tyler WB: Diffuse cutaneous mastocytosis. Treatment with oral psoralen plus UVA. Arch Dermatol 1996;132:1429–1430.
Smith ML, Orton PW, Chu H, Weston WL: Photochemotherapy of dominant, diffuse cutaneous mastocytosis. Pediatr Dermatol 1990;7:251–255.
Godt O, Proksch E, Streit V, Christophers E: Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997;195:35–39.
Stege H, Schöpf E, Ruzicka T, Krutman J: High-dose UVA1 for urticaria pigmentosa. Lancet 1996;347:64.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.